ReviewOphthalmology and therapy2023
Adherence and Persistence to Medical Therapy in Glaucoma: An Overview.
Review in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia.The Lancet. Global health · 2026Trial
- Trial
- Trial
- Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- The Impact of the COVID-19 Pandemic on Adherence and Persistence to Glaucoma Therapy: A Retrospective Italian Cohort Study.Advances in therapy · 2026Article
- [Experiences of glaucoma patients : Evaluation of the survey conducted by the Federal Association Glaucoma Self-help and the DOG Glaucoma Section].Die Ophthalmologie · 2026Article
- Should Schlemm Canal-Based MIGS Be Combined with Cataract Surgery in Patients Receiving Topical Glaucoma Therapy? A Cataract Surgeon-Oriented Review.Journal of clinical medicine · 2026Review
- Association of Comprehensive Geriatric Assessment with Knowledge- and Technique-Related Eye Drop Adherence Problems in Glaucoma Assessed Using the Shimane University Glaucoma Eye Drop Adherence Questionnaire.Journal of clinical medicine · 2026Article
- Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.Ophthalmology and therapy · 2026Article
- Establishing Consensus on the Appropriate Tool for Measuring Adherence to Glaucoma Medication in a Sub-Saharan African Population: A Multidisciplinary Delphi-Based Study.Public health challenges · 2026Article
- Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care: A Narrative Review.Ophthalmology and therapy · 2026Review
- A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Preservative-Free Gel-Formulated Glaucoma Therapies: Learning from the Past, Looking to the Future.Advances in therapy · 2025Review
- Micropulse Laser Trabeculoplasty in Glaucoma: Efficacy and Safety in a Clinical Cohort.Medicina (Kaunas, Lithuania) · 2025Article
- Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma.Scientific reports · 2025Observational
- Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.Ophthalmology and therapy · 2025Review
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- From a Fish Protein to a Novel Glaucoma Therapeutic: Stanniocalcin-1 for Intraocular Pressure Reduction.Advances in ophthalmology and optometry · 2025Article
- Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies.Advances in therapy · 2025Article
- Epinastine Eyelid Cream as a Practical Option for Patients With Glaucoma on Multidrug Topical Therapy: A Case Report.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a group of progressive optic neuropathies characterized by loss of retinal ganglion cells and visual field deterioration. Despite the fact that the underlying pathophysiology of glaucoma remains unknown, elevated intraocular pressure (IOP) is a well-established risk factor, and the only factor that can be modified. Robust evidence from epidemiological studies and clinical trials has clearly demonstrated the benefits of IOP control in reducing the risk of glaucoma progression. IOP-lowering therapy by the means of eye drops remains a first-line treatment option. However, like other chronic and asymptomatic conditions, many patients with glaucoma have difficulties in maintaining high rates of adherence persistence to prescribed medications. On average, patients with chronic medical conditions take 30-70% of the prescribed medication doses, and on average 50% discontinue medications in the first months of therapy. The ophthalmic literature shows similarly low rates of adherence to treatment. Indeed, poor adherence is associated with disease progression and increased complication rates, as well as healthcare costs. The present review analyzes and discusses the causes of variability of the adherence to the prescribed drugs. The education of patients about glaucoma and the potential consequences of insufficient adherence and persistence seems fundamental to maximize the probability of treatment success and therefore prevent visual disability to avoid unnecessary healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.